3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Active not recruiting
6
Recruiting
2
Not yet recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Urinary Bladder Neoplasms
2
Recurrence
1
Non-Muscle Invasive Bladder Neoplasms
1
Carcinoma in Situ
1
Interventions
Specimen Handling
481
pembrolizumab
454
Magnetic Resonance Spectroscopy
419
Carboplatin
321
Cyclophosphamide
314
Biopsy
272
Cisplatin
264
Radiotherapy
239
Paclitaxel
226
Gemcitabine
222
Bevacizumab
212
Nivolumab
189
fludarabine
183
venetoclax
172
Drug Therapy
165
Dexamethasone
157
Blood Specimen Collection
156
Oxaliplatin
154
Injections
152
Capecitabine
152
Fluorouracil
144
Docetaxel
142
Standard of Care
136
Radiosurgery
136
Rituximab
125
Pemetrexed
115
durvalumab
113
atezolizumab
110
Leucovorin
110
Radiation
105
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recruiting
×
BCG Vaccine
×
1 year
×
Clear all
NCT06833073
2026-05-28
INTerpath-011
Merck Sharp & Dohme LLC
Phase 2
Recruiting
308 enrolled
NCT05037279
2026-03-20
EVER
Verity Pharmaceuticals Inc.
Phase 3
Recruiting
540 enrolled